Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: 29 | History Defined

Why Moderna Shares Are Trading Lower Following Novavax's Earnings Report

Moderna Inc (NASDAQ: MRNA) shares are trading lower by 3.15% at $131.52.

Fourth Covid booster vaccine 'significantly' improves protection over just three jabs

Fourth Covid booster vaccine 'significantly' improves protection over just three jabs

It is "over and above" the level of protection that people who have had their third jab receive, according to the latest research.

Covid vaccines safe for pregnant women and cut stillbirth risk, says review

Covid vaccines safe for pregnant women and cut stillbirth risk, says review

Chance of stillbirth reduced by 15%, researchers find, after examining studies and trials that enrolled 117,552 women

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourth booster ‘significantly’ increases Covid protection

Levels of antibodies waned in period between third jabs and fourth boosters

Covid: ‘Vaccine ceiling’ approaching for some as study suggests fourth jab may not be necessary

A ‘hint’ that some people might have already reached ‘ceiling’ in terms of protection they could acquire from fourth jab

The Independent UK

Morning Brief: Top Financial Stories Dominating on Monday, May 9

CNBC Ford Motor Selling 8M Shares Of Rivian Automotive

Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ

Moderna Inc (NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 vaccine, arguing that the companies may only pursue their claims by seeking royalties from the federal government.

inkl

Read news from The Economist, FT, and more,
with one subscription

Looking At Moderna's Recent Whale Trades

Looking At Moderna's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

US Drug Regulator Limits Use of J&J Covid Vaccine

US Drug Regulator Limits Use of J&J Covid Vaccine

The US said Thursday only adults who "have personal concerns" about mRNA vaccines, access issues or medical reasons for refusing them may now receive the Johnson & Johnson Covid shot, which has been linked to a rare but serious clotting condition. The vaccine, which was authorized as a single shot,…

Asharq Al-Awsat

Check Out What Whales Are Doing With MRNA

Check Out What Whales Are Doing With MRNA

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Where Moderna Stands With Analysts

Where Moderna Stands With Analysts

Analysts have provided the following ratings for Moderna (NASDAQ:MRNA) within the last quarter:

Commentary: COVID won’t become endemic until we have a vaccine for kids under 5

Last week, Moderna became the first manufacturer to officially ask the Food and Drug Administration to approve its COVID-19 vaccine for children under 6 years old. One of three companies with authorized COVID-19 vaccines in the United States, Moderna made the request a month after saying its data showed efficacy…

Los Angeles Times

Mid-Day Market Update: Dow Rises 100 Points; Lyft Shares Plummet

Mid-Day Market Update: Dow Rises 100 Points; Lyft Shares Plummet

U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 100 points on Wednesday.

Mid-Morning Market Update: Markets Mixed; Nasdaq Tumbles 100 Points

Mid-Morning Market Update: Markets Mixed; Nasdaq Tumbles 100 Points

U.S. stocks traded mixed this morning, with the Nasdaq dropping more than 100 points on Wednesday.

Get all your
news in one place.

100's of premium titles.
One news app.

The Conversation

Will new vaccines be better at fighting coronavirus variants? 5 questions answered

The first three coronavirus vaccines earned Emergency Use Authorization more than a year ago. To date, no other vaccines have been put into use in the U.S – but that will soon change. More than 40 vaccines are undergoing clinical trials in the U.S., employing a number of different approaches…

Here's Why Moderna Shares Are Trading Higher After Q1 Earnings Today

Moderna Inc (NASDAQ:MRNA) reports a Q1 EPS of $8.58, compared to the $2.84 posted a year ago, handsomely beating the consensus estimate of $5.21. Total revenue was $6.1 billion compared to $1.9 billion in Q1 FY21, primarily due to increased product sales. The revenue consensus was $4.43 billion. Product sales were $5.9…

Moderna: Q1 Earnings Insights

Moderna (NASDAQ:MRNA) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

The Independent UK

Pfizer hopes to submit little-kid vaccine data by early June

Pfizer now hopes to tell U.S. regulators how well its COVID-19 vaccine works in the littlest kids by early June

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill

Moderna Bullish On COVID-19 Vaccine For Younger Kids To Be Ready Next Month: Reuters

Moderna Inc's (NASDAQ:MRNA) chief medical officer said that its COVID-19 vaccine for children under six years old would be ready for review by the FDA panel when it meets in June. "I think the FDA now has all of the core fundamental data they need to be able to begin an application review.…

Here's What To Watch On Moderna As The Stock Flies Higher

Moderna, Inc (NASDAQ: MRNA) was trading over 8% higher at one point on Monday morning, bouncing up within a descending channel pattern on the daily chart.

American Express And 2 Other Stocks Insiders Are Selling

Gold futures traded lower by around 2.5% on Monday. Investors, meanwhile, focused on some notable insider trades.

Pressure builds for COVID vaccines approval for littlest kids

Moderna's request for approval of its COVID -19 vaccine in children under six years amps up pressure on the Food and Drug Administration to act quickly to approve the shots.

Chinese Omicron-specific mRNA COVID vaccine candidate to be trialed in UAE

China's Suzhou Abogen Biosciences Co said its COVID-19 vaccine candidate using the messenger RNA (mRNA) technology and targeting the Omicron variant has obtained clinical trial approval in the United Arab Emirates.

FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For Kids, Plus Novavax EUA

The FDA has set up June meeting dates to review COVID-19 vaccine submissions, noting that the dates are tentative as none of the submissions are complete. The agency reserved June 8, 21, and 22 for virtual meetings of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) to review Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE)…

1 … 28 29 30 31

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Wall Street Journal

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

417,947 stories

United Arab Emirates

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play